ArticleJournal of geriatric cardiology : JGC2026
Impact of heart failure on skeletal muscle: an overview.
Article in Journal of geriatric cardiology : JGC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Skeletal muscle histological remodeling precedes functional impairment in a muscle-specific manner following monocrotaline-induced heart failure in rats.European journal of applied physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a complex clinical syndrome that promotes high morbidity and multi-systemic damage. Skeletal muscle can be directly affected by HF through a loss of physical capacity and various inflammatory, hormonal, and metabolic mechanisms observed in this cardiac condition, which collectively contribute to a high prevalence of sarcopenia in HF patients. Therefore, the aim of this review was to compile the main recent clinical and epidemiological data on muscle health in HF patients. Nine studies were selected from systematic reviews and clinical trials, which demonstrated a high prevalence of sarcopenia in patients with HF, particularly in males, hospitalized patients, the elderly, and those with HF with reduced ejection fraction. Oxidative stress markers and higher levels of natriuretic peptides were also observed in HF patients who exhibited damaged muscle parameters. Furthermore, the overall deterioration of prognosis in HF was associated with criteria defining sarcopenia, such as low muscle strength and lean mass loss. These findings reinforce the importance of evaluating skeletal muscle in HF patients, which can provide improvements in morbidity and functionality.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.